Kyverna Therapeutics KYTX
NASDAQ KYTX
$6.80 -0.04 (-0.58%)
At close: Sep 30, 2026 · 4:00 PM EDT

Kyverna Therapeutics (KYTX) Debt Ratio (2025 - 2026)

Updated

Kyverna Therapeutics' Debt Ratio came in at 0.11 for Q2 2026, up 17.3% from the prior quarter.

Analysis

Kyverna Therapeutics (KYTX) Debt Ratio (2025 - 2026) Analysis & Trends

For FY2025, Kyverna Therapeutics' Debt Ratio was 0.08.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 0.24
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 0.52
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn 0.42
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn 0.31
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn 0.00
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 0.60
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn 0.53
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 0.31
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn -
10 Kyverna Therapeutics 421.14 Mn 421.14 Mn - 0.11
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 0.11
Mar 31, 2026 0.10
Dec 31, 2025 0.08
API Access

Kyverna Therapeutics Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=KYTX&period=max&api_key=YOUR_API_KEY